DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of the Inflammatory Bowel Disease, historical and forecasted epidemiology as well as the Inflammatory Bowel Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Inflammatory Bowel Disease Market with DelveInsight’s In-Depth Report @ Inflammatory Bowel Disease Market Size
Key Takeaways from the Inflammatory Bowel Disease Market Report
- As per DelveInsight’s estimates, the current market of Inflammatory Bowel Disease (IBD) is valued at approximately USD 20 billion for the 7MM in 2025.
- In 2025, the total diagnosed prevalent cases of IBD in the US were found to be approximately 2,800,000, which was highest among the 7MM.
- Among the total diagnosed prevalent cases of IBD, the majority of cases were accounted for by Ulcerative colitis, accounting for approximately 57% of total IBD cases in the US in 2025.
- In 2025, there were more than one million cases falling in the age group of 18-44 years, which was highest among other age groups for IBD in the US.
- In 2025, there were approximately 1,116,000 mild cases of IBD in the US, while the majority of cases, around 1,837,000, were classified as moderate to severe, highlighting the significant severity and progression of the disease.
- In 2025, the US accounted for the highest number of treated cases of IBD, with approximately 3,575,000 cases, expected to increase with advancements in treatment options and a lucrative pipeline.
- Crohn’s disease is typically more severe than ulcerative colitis but is slightly less common. The disease can occur at any age, but Crohn’s disease is most often diagnosed in adolescents and adults between 20 and 30.
- The leading Inflammatory Bowel Disease Companies such as Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, Abivax, Morphic Therapeutic, Merck, RedHill Biopharma, and others.
- Promising Inflammatory Bowel Disease Therapies such as RINVOQ (upadacitinib), STELARA (ustekinumab), ABX464 (obefazimod), RHB-204, MORF-057, tulisokibart, and others.
Stay ahead in the Inflammatory Bowel Disease market with DelveInsight’s Strategic Report @ Inflammatory Bowel Disease Market Outlook
Inflammatory Bowel Disease Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Cases of Inflammatory Bowel Disease
- Type-specific Cases of Inflammatory Bowel Disease
- Severity-specific Cases of Inflammatory Bowel Disease
- Age-specific Cases of Inflammatory Bowel Disease
- Treatable Cases of Inflammatory Bowel Disease
Download the report to understand which factors are driving Inflammatory Bowel Disease market research @ Inflammatory Bowel Disease Prevalence
Marketed Inflammatory Bowel Disease Therapies
- RINVOQ (upadacitinib): AbbVie RINVOQ is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) which modulate intracellular activity including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. In March 2022, the US FDA approved RINVOQ for the treatment of adults with moderately to severely active ulcerative colitis.
- STELARA (ustekinumab): Janssen Pharmaceuticals STELARA is a human monoclonal antibody. It mediates the body’s T-cell response by acting as an antagonist against interleukin-12 (IL12) and interleukin-23 (IL23). IL-12 and IL-23 are cytokines that modulate lymphocyte function and have been implicated in the pathogenesis of inflammatory diseases. In September 2016, the US FDA approved STELARA for the treatment of adults with moderately to severely active Crohn’s disease.
Emerging Inflammatory Bowel Disease Therapies
- ABX464 (obefazimod): Abivax ABX464 is an oral small-molecule drug candidate developed by Abivax with potent anti-inflammatory properties. It selectively upregulates microRNA-124 (miR-124), a natural regulator of the inflammatory response, which leads to decreased cytokine production and immune cell activity, helping to reduce inflammation. Currently, it is being evaluated in various Phase III trials to treat moderately to severely active Ulcerative Colitis, with topline data readout expected in late Q2, 2026. For Crohn’s disease, the asset is currently being evaluated in a Phase IIb induction study, with topline results anticipated in Q4 2026. In January 2026, Abivax announced that ABTECT-UC Phase III maintenance topline results for ABX464 are expected in late Q2 2026, followed by a planned US regulatory filing in late 2026.
- RHB-204: RedHill Biopharma RHB-204 is an investigational, proprietary, fixed-dose, orally administered antibiotic combination therapy containing clarithromycin, rifabutin, and clofazimine in development for the treatment of moderate to severe Crohn’s disease in Mycobacterium avium subspecies paratuberculosis-positive (MAP+) patients. RHB-204 is currently being evaluated in a planned innovative Phase II clinical study.
To know more about Inflammatory Bowel Disease treatment guidelines, visit @ Inflammatory Bowel Disease Treatment Market Landscape
Inflammatory Bowel Disease Therapies and Companies
- RINVOQ (upadacitinib): AbbVie
- STELARA (ustekinumab): Janssen Pharmaceuticals
- ABX464 (obefazimod): Abivax
- RHB-204: RedHill Biopharma
- MORF-057: Morphic Therapeutic
- tulisokibart: Merck
- risankizumab (SKYRIZI): AbbVie
- duvakitug (TEV-574/SAR447189): Sanofi/Teva
Inflammatory Bowel Disease Market Dynamics The Inflammatory Bowel Disease market dynamics have undergone significant changes over the years. The rising disease burden, with increasing prevalence of IBD particularly in developed regions, is contributing significantly to market expansion. Advancements in medical research and development have brought innovative biologics, small molecules, and targeted therapies to the market, improving patient outcomes and driving market growth. A robust pipeline with multiple late-stage assets is expected to transform the treatment landscape and provide new therapeutic options. The shift toward precision medicine, with growing focus on molecular characterization and personalized treatment approaches, is expected to enhance treatment efficacy. Additionally, the unmet medical needs, including limitations of current therapies, lack of predictive biomarkers, and variability in patient response, create significant opportunities for novel drug development. The most common medications used to treat Inflammatory Bowel Disease include ASA anti-inflammatory drugs, anti-TNF, IL antagonists, JAK inhibitors, TLR 9 agonists, and integrins, among others.
Learn more about the FDA-approved drugs for Inflammatory Bowel Disease @ Drugs for Inflammatory Bowel Disease Treatment
Scope of the Inflammatory Bowel Disease Market Report
- Coverage- 7MM
- Study Period- 2022-2036
- Inflammatory Bowel Disease Companies- Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, Abivax, Morphic Therapeutic, Merck, RedHill Biopharma, and others
- Inflammatory Bowel Disease Therapies- RINVOQ (upadacitinib), STELARA (ustekinumab), ABX464 (obefazimod), RHB-204, MORF-057, tulisokibart, risankizumab, duvakitug, and others
- Inflammatory Bowel Disease Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Bowel Disease Market Access and Reimbursement
Table of Content
- Key Insights
- Report Introduction
- Executive Summary
- Inflammatory Bowel Disease (IBD): Market Overview at a Glance
- Key Events
- Epidemiology and Market Forecast Methodology
- Disease Background and Overview
- Treatment
- Epidemiology and Patient Population
- Patient Journey
- Marketed Products
- Emerging Therapies
- Inflammatory Bowel Disease (IBD): Seven Major Market Analysis
- SWOT Analysis
- Unmet Needs
- KOL Views
- Reimbursement and Market Access
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.
Contact Information
Kanishk
